M.Sc, M.Tech. Bioinformatics/ Biotechnology/ Life science, Biomedical Sciences/Engineering, Veterinary or relevant Life science discipline), with minimum of 55% marks.
First Class M.Sc in Biotechnology. Handling of yeasts; Yeast culturing, purification, staining, cell counts, viability estimation, growth curve estimation, Sedimentation study etc.
Postgraduate degree in Basic Sciences / Professional Courses NET/GATE qualification required. 1 -2 years of hands-on experience in cell culture / molecular biology are preferred.
Looking for B.Pharm, M.Pharm candidates as Product Manager to develop, implement, and maintain long-term strategies for high-potential products in our current and future portfolio, aiming to maximize market share and profitability through strategic planning and execution.
To design and conduct experiments for preformulation, formulation optimization of Microsphere and long acting complex non oral dosage form based on QbD approach. To execute the experiments as per Design of experiments
Handling the Incidents / Deviations, Out of Trends, Out of Specification including investigations, Corrective and Preventive actions follow up and closure. Monitoring of analytical activities in Quality control laboratory.
Stallion Laboratories incorporated in 1988 as an integrated private sector Pharmaceutical Formulation Manufacturer, has acquired an unmatched record of managing niche product in formulations with a WHO GMP approved production facility
Seeking an exceptional leader to Head Pharmacovigilance and Medical Affairs including medical information function for Dr. Reddys North America Generics and affiliates as well as Dr. Reddys Canada
Develop and execute quality and compliance monitoring activities for PS processes within area of expertise to support a robust GVP Quality Management System.
Develop and present key Competitive Intelligence deliverables for multiple internal business partners, primarily R&D, Commercial, and Legal stakeholders
The U.S. Food and Drug Administration, USFDA has delivered a strong criticism to Amneal Pharmaceuticals, issuing a warning letter on August 27, 2025, for serious infractions in manufacturing practices at its Gujarat facility.